FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology and pharmaceutics, namely to medicines for ophthalmic use. Agent for treating ocular diseases comprises calcium-phosphate coated nanoparticles comprising the active substance and water. Calcium phosphate nanoparticles include an amorphous phase, which is amorphous calcium phosphate, and a crystalline structure that is brushite. Coating is made of chitosan. Nanoparticles have a hydrodynamic radius of 30 to 130 nm, surface charge +16±4 mV. pH of aqueous solution is 6.2–7.5. Agent may be in form of a freeze dried powder. Product has prolonged action. New agent is instillated into conjunctival cavity at effective concentration of 0.1–0.3 %.
EFFECT: technical result of proposed group of inventions is possibility of reducing the dose and frequency of using an ophthalmic agent with a reduction in local and systemic side effects.
7 cl, 1 dwg, 6 ex, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR REDUCING INTRAOCULAR PRESSURE AND METHOD OF USE THEREOF | 2022 |
|
RU2815996C1 |
METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
METHOD OF REDUCING INTRAOCULAR PRESSURE | 2011 |
|
RU2472471C1 |
LIPOSOMAL SUSPENSIONS STABILISER | 2015 |
|
RU2642786C2 |
MEANS FOR DELIVERY OF ACTIVE AGENT | 2017 |
|
RU2669354C1 |
PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION IN TREATING INFLAMMATORY EYE DISEASES AND METHOD FOR USING IT | 2012 |
|
RU2508123C1 |
METHOD FOR PREDICTION OF DEVELOPING NEURODEGENERATIVE DISEASES, UNDERLYING THE PATHOGENESIS OF WHICH IS GAMMA-SYNUCLEINOPATHY | 2018 |
|
RU2703430C1 |
METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY USING LIPOSOME-ASSOCIATED MELPHALAN IN AN EXPERIMENT | 2021 |
|
RU2772520C1 |
DEXAMETHASONE CONJUGATE WITH SYNTHETIC STATISTICAL POLYPEPTIDE | 2020 |
|
RU2792146C2 |
METHOD FOR EYE ISCHEMIA SIMULATION | 2016 |
|
RU2620014C1 |
Authors
Dates
2018-06-15—Published
2016-09-14—Filed